Vyfemla NDC 68180-875

NDC codes

FDA NDC Directory

Product NDC (as listed)68180-875Labeler and product segments. Claims need a package NDC.

Product NDC at billing width68180-0875Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
68180-875-73	68180087573	3 POUCH in 1 CARTON (68180-875-73) / 1 BLISTER PACK in 1 POUCH / 1 KIT in 1 BLISTER PACK * 21 TABLET in 1 BLISTER PACK (68180-495-74) * 7 TABLET in 1 BLISTER PACK (68180-500-74)Marketed from Nov 4, 2020

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Vyfemla
Generic name (nonproprietary): norethindrone and ethinyl estradiol
Dosage form: Kit
Labeler: Lupin Pharmaceuticals, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 201886
Marketing start: Nov 4, 2020
Listing expires: Dec 31, 2026
Identifiers: Product ID 68180-875_c44722bd-9db7-4ea4-b150-7d514b1bc4f7SPL ID c44722bd-9db7-4ea4-b150-7d514b1bc4f7SPL set ID 175ce5c4-d332-4c97-a0b8-10821dc813efRxCUI 238015, 748797, 749736, 1485332

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N468180087573 followed by a unit qualifier and the quantity

Package 68180-0875-73. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 19, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

INDICATIONS AND USAGE Oral contraceptives are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. Oral contraceptives are highly effective. Table 1 lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. TABLE 1 LOWEST EXPECTED AND TYPICAL FAILURE RATES DURING THE FIRST YEAR OF CONTINUOUS USE OF A METHOD % of Women Experiencing an Accidental Pregnancy in the First Year of C…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)